France / Valneva: Small, but Poised for COVID-19 Vaccine Success
While Big Pharma companies like Pfizer, Janssen and AstraZeneca, have grabbed the headlines over the past year for…
Top Stories
Russia / Biocad Ramps up Sputnik V Manufacturing; Unlicensed Remdesivir Generics; Chinese Vaccine Rejection
The latest news from Russian pharma, including Biocad’s ramping up of Sputnik V COVID-19 vaccine manufacturing, Geropharm’s deal to produce insulin in Venezuela, the bypassing of Gilead’s Remdesivir IP, and…
China / Top 10 Pharma Companies 2020
The Top 10 Chinese pharma companies for 2020 ranked by overall revenues. Taken from Fortune magazine’s 2020…
Italy / Mandatory COVID-19 Vaccines for Healthcare Workers; Chiesi & Angelini’s AI Investments; Sputnik V Manufacturing
The latest from Italian pharma, including the government’s decision to make COVID-19 vaccines mandatory for all…
The Long Read / Switzerland: Staying the Course
This article forms part of Healthcare & Life Sciences Review: Switzerland February 2021, a comprehensive…
Turkey / The Impact Of Brexit On CE Certificates Issued By UK Notified Bodies
The shockwaves from the UK’s exit from the European Union have resounded across the continent, including in…
APAC / Novartis APAC Oncology Head & Singapore Country President Kevin Zou
Kevin Zou highlights Novartis Oncology’s footprint and priorities in the diverse Asia-Pacific region, the…
In Conversation
Ashish D Pal – Managing Director, MSD Singapore, Malaysia & Brunei Cluster; President, Singapore Association of Pharmaceutical Industries (SAPI); Vice-President, Pharmaceutical Association of Malaysia (PhAMA)
MSD’s Ashish Pal describes how he led the Singapore, Malaysia, and Brunei cluster through a challenging 2020; the importance of leveraging learnings from the past year to create a more resilient, agile, and digitally-focused affiliate; and why increased levels of public-private collaboration in the region are vital to building a sustainable and enabling environment for access to innovative medicines and…
Latest Reports
Focus on USA
US FDA Drug Approvals 2020
In 2020, the US FDA's Center for Drug Evaluation & Research (CDER) approved…
NORD Chief Strategy Officer on Health Equity’s Vital…
With Rare Disease Day coming up on February 28th, one of the leading…
5 US Rare Disease Start-Ups to Watch
Following on from our profile on five of the most promising clinical-stage…
Securing the Conditions to Secure Our Meds
The AAM’s Dan Leonard highlights the savings impact that generic and…
Read more: USA >>
Focus on Singapore
Singapore: Finding the Right Pharma Talent Post-COVID
Singapore – despite its modest USD 1.22 billion domestic market – has long…
Medtech’s Post-COVID Paradigm in APAC
At USD 150 billion, Asia-Pacific is home to the world’s second largest medtech…
APAC: Prestige & HH&L IPO News; Cold Chain Vaccine…
The latest pharma news from the Asia-Pacific region, including upcoming IPOs for…
HSA: APAC’s Regulatory Gold Standard
As the most important pharma hub in its region, and one of the most important…
Read more: Singapore >>
Focus on Europe
Jazz’s $7.2 Billion GW Pharma Deal: A Major Boost for…
The first day of March 2013 also marked a first for GW Pharmaceuticals. On that…
After Brexit: Focus on the New Pharmaceutical Strategy for…
Writing in the February edition of DIA’s Global Forum magazine, Thomas Kühler…
Latvia: Striving to Catch Up to its Neighbours on Innovation…
Dr Valters Bolevics, director general of the Association of International…
Read more: Europe >>
Focus on Vaccines
LatAm Pharma News: COVAX Rollout in Colombia; União Quimica…
The latest LatAm pharma news, including COVID-19 vaccine rollouts in Colombia,…
Italy Pharma News: Mandatory COVID-19 Vaccines for…
The latest from Italian pharma, including the government’s decision to make…
Valneva: Small, but Poised for COVID-19 Vaccine Success
While Big Pharma companies like Pfizer, Janssen and AstraZeneca, have grabbed…
German Pharma: Highest Honours for BioNTech Founders;…
A roundup of some of the most important recent news from German pharma,…
Read more: Vaccines >>
Focus on China
New Drug Approvals in China 2020
The Chinese NMPA’s drug approval list for 2020 includes a surge in approvals…
China: AstraZeneca/Junshi anti-PD-1 Tie-Up; New UK Biologics…
The latest from Chinese pharma, including a new deal between AstraZeneca and…
China: Yangtze River Pharmaceutical Group (YRPG) in Profile
One of the largest domestic pharma companies in China (ranking number one from…
Public Insurance Coverage for Rare Disease Patients in…
Kevin Rufang Huang, president and founder of the Chinese Organization for Rare…
Read more: China >>
Focus on MEA
Saudi Arabia: SFDA CEO Sets Out Strategic Priorities
In a recent conversation with PharmaBoardroom, Prof. Hisham Bin Saad Al-Jadhey,…
MEA: Pfizer’s Saudi Transformation; Urgent Call for Arab…
The latest news from Middle East & North African pharma, including…
MEA: Iran looks to Cuba for COVID-19 Vaccine; Israel Leads…
The latest COVID-19 vaccine news from the Middle East & Africa (MEA) region,…
MEA Roundup: Turkey’s Pharma Debt; Saudi Market Rise; UAE…
A roundup of the latest from the Middle East & Africa region, including…
Read more: MEA >>
Focus on Switzerland
Ichnos CEO on Glenmark Legacy, Biotech Transformation &…
After an illustrious career in oncology R&D, contributing greatly to the…
Building a Health Data Ecosystem in Switzerland
Although Switzerland is ahead of many of its competitors in Europe on levels of…
ISREC’s Susan Gasser: A “Hard-Nosed” Approach to…
After 15 years as director at the Friedrich Miescher Institute for Biomedical…
Swiss Pharma: Staying the Course
This article forms part of Healthcare & Life Sciences Review: Switzerland…